jnj-7777120 and Dermatitis--Allergic-Contact

Histamine facilitates development of eczematous lesions in chronic allergic contact dermatitis. In addition to the well-known corticosteroid treatments, H1 receptor (H1R) antagonists also have been used. This study observed effects of histamine H4 receptor (H4R) antagonist usage with H1R antagonist in a murine chronic allergic contact dermatitis model, developed by repeated percutaneous challenge to the dorsal skin with 2,4,6-trinitro-1-chlorobenzene (TNCB). The H1R antagonist olopatadine hydrochloride and/or the H4R antagonist JNJ7777120 was then administered. Combination therapy was more effective than H1R antagonist monotherapy. Serum IgE and levels of interleukin (IL)-4, IL-5 and IL-6 (Th2 cytokines) in eczematous lesions decreased with combined therapy. Combined therapy with H1R and H4R antagonists counteracts the disadvantages of each as monotherapeutic agents and potentially represents a new strategy for the treatment of chronic allergic contact dermatitis.

Topics: Animals; Dermatitis, Allergic Contact; Dibenzoxepins; Disease Models, Animal; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Immunoglobulin E; Indoles; Interleukin-4; Interleukin-5; Interleukin-6; Mice; Mice, Inbred C57BL; Olopatadine Hydrochloride; Picryl Chloride; Piperazines; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4